BioStem Technologies Appoints SEC-Qualified Financial Expert Jodi Ungrodt to Board as Audit Committee Chair

BioStem Technologies has announced the appointment of Jodi Ungrodt to its Board of Directors, where she will also serve as Chair of the Audit Committee, effective March 18, 2026. Ungrodt brings nearly three decades of financial leadership to the role, having spent her career as a senior partner at Ernst & Young advising life sciences companies on initial and secondary public offerings, business combinations, risk assessment and regulatory compliance. She is qualified to serve as a financial expert under SEC, NYSE, and NASDAQ rules.

Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated that Ungrodt's appointment comes as the company undertakes expansion beyond chronic wound care and plans to raise its profile in the public markets in 2026. Her twenty-nine years of life sciences accounting experience at Ernst & Young, along with her track record advising more than thirty IPOs and deep regulatory expertise, will strengthen board governance during this pivotal time. BioStem is an emerging leader in placental and umbilical cord–derived tissue products used by clinicians across various medical specialties, with a proprietary allograft portfolio derived from donated birth tissue.

As Audit Committee Chair, Ungrodt will oversee the company's financial reporting, internal controls and risk management practices. Her prior experience includes serving as Chair of the Audit Committee for Feeding San Diego, where she provided accounting, budgeting and risk assessment guidance for over a decade. She is also an Advisory Board Member for Life Science Cares. During her tenure at EY, Ungrodt served more than 70 companies across the Life Sciences sector. Ungrodt expressed excitement about joining BioStem's board, noting the company stands out as one of the most innovative in the MedTech sector, driven by strong momentum in the chronic wound market and recent expansion into acute applications of its industry-leading technologies.

Ungrodt replaces former board member Brandon Poe, who accepted the role of BioStem's chief financial officer in August 2025. Poe brings more than 25 years of finance leadership experience across healthcare and life sciences sectors and served on BioStem's Board of Directors for three years before joining the organization. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks, established in compliance with current Good Tissue Practices and current Good Manufacturing Processes. The company's portfolio includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines, with more information available at https://tinyurl.com/bsemnewsroom.